Physician

Adam Rea Kuykendal, M.D.

According to 2025 Medicare claims, Adam Kuykendal, M.D. (NPI: 1447412713) practices hematology/oncology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Mecklenburg, NC. This provider's primary affiliated billing organization is THE PRESBYTERIAN HOSPITAL (NPI: 1275256422; TIN: 560554230) and primary practice location at 28105-4658. Kuykendal is affiliated with the Novant Health Accountable Care Organization I, LLC (ACO ID: A3504), participating under the MSSP model.

Kuykendal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 279 traditional Medicare patients, billed 1,288 HCPCS/CPT codes, and received $62,419 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 935 prescription claims across 156 beneficiaries totaling $2,610,879 in drug costs, led by Xtandi (Enzalutamide). DME data shows 46 claims. Open Payments data shows 1 records totaling $334. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $567,341 to $2,610,879. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,798 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	256	762	$51,015
2016	293	982	$62,606
2017	280	963	$60,473
2018	306	1,033	$65,131
2019	290	1,052	$67,324
2020	267	987	$64,343
2021	273	897	$75,848
2022	282	828	$66,585
2023	272	797	$61,227
2024	279	1,288	$62,419

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	113	838	$567,341
2016	141	882	$940,888
2017	139	827	$1,265,418
2018	143	928	$1,827,910
2019	155	1,014	$2,304,087
2020	159	1,085	$2,424,052
2021	140	891	$2,540,435
2022	137	828	$2,492,516
2023	135	740	$1,852,814
2024	156	935	$2,610,879

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	24	$3,673
2016	N/R	52	$17,939
2017	N/R	N/R	N/R
2018	N/R	51	$9,177
2019	22	109	$10,578
2020	N/R	11	$2,025
2021	N/R	N/R	N/R
2022	N/R	14	$1,196
2023	N/R	72	$11,719
2024	N/R	46	$1,369

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	39	39	$126
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	63	98	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	168	489	$66
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	60	75	$37
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	179	518	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	45	1,350	$398,928
Revlimid	Lenalidomide	16	448	$341,246
Abiraterone Acetate	Abiraterone Acetate	112	3,360	$334,772
Pemazyre	Pemigatinib	13	273	$244,311
Nubeqa	Darolutamide	13	390	$171,997

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$973
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$245
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$334	Astellas Pharma Global Development
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Rea Kuykendal, M.D.?

Tedicare shows public-source Medicare data for Adam Rea Kuykendal, M.D. (NPI 1447412713), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Rea Kuykendal, M.D. have ACO affiliation data?

Adam Rea Kuykendal, M.D. is shown with ACO affiliation data for Novant Health Accountable Care Organization I, LLC (MSSP, ACO ID A3504).

What billing organization is linked to Adam Rea Kuykendal, M.D.?

Adam Rea Kuykendal, M.D. is linked to THE PRESBYTERIAN HOSPITAL (billing NPI 1275256422) in the available physician profile data.

Does Adam Rea Kuykendal, M.D. have Open Payments data?

Adam Rea Kuykendal, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.